EARLY PHASE CLINICAL TRIAL TO EVALUATE ANTIVIRALS (APP)

NIH RePORTER · NIH · N01 · $6,142,134 · view on reporter.nih.gov ↗

Abstract

To support a Phase I clinical trial to evaluate a promising new antiviral. The drug is intended to be used in an outpatient setting, a key objective of the Antiviral Program for Pandemics funded by the American Rescue Plan.

Key facts

NIH application ID: 10710287
Project number: 75N91019D00024-0-759102200017-1
Recipient: LEIDOS BIOMEDICAL RESEARCH, INC.
Principal Investigator: THERESA ENGEL
Activity code: N01
Funding institute: NIH
Fiscal year: 2022
Award amount: $6,142,134
Award type: —
Project period: 2022-09-19 → 2024-09-18